← 483 OBSERVATION EXPLORER

FDA 483 OBSERVATION · #681 OF 1,000 MOST-CITED

Risk-based approach not applied to QMS processes

FDA cited this observation 25 times across 25 firms in recent inspections. Below: how it breaks down by program area and fiscal year, and real examples of how FDA worded it on Form FDA 483.

BY PROGRAM AREA
Devices25
BY FISCAL YEAR
FY202625

How FDA worded it — real examples

A risk-based approach to the control of the appropriate processes needed for the quality management system has not been adequately applied.

Surgical Theater Inc · Beachwood, Ohio · Devices · 2026-06-11

A risk-based approach to the control of the appropriate processes needed for the quality management system has not been applied.

MANSBACH HEALTH TOOLS LLC · Potomac, Maryland · Devices · 2026-06-02

A risk-based approach to the control of the appropriate processes needed for the quality management system has not been applied.

Perry Dynamics Inc · Decatur, Illinois · Devices · 2026-05-20

A risk-based approach to the control of the appropriate processes needed for the quality management system has not been adequately applied.

Miami Fat Supply, Inc · Fruitland Park, Florida · Devices · 2026-05-15

A risk-based approach to the control of the appropriate processes needed for the quality management system has not been applied.

YourSteps Health Inc · Eagan, Minnesota · Devices · 2026-05-06

A risk-based approach to the control of the appropriate processes needed for the quality management system has not been adequately applied.

Enterra Medical, Inc. · Minneapolis, Minnesota · Devices · 2026-05-04

Related SPEQ references

Where to read the requirements behind this observation area on SPEQ. These are SPEQ's topic and audience pages — not an FDA classification of the citation.

Quality risk managementMedical devices

Examples are a representative sample of FDA's published inspection observations. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →